Coldstream Capital Management’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $4.96M | Sell |
35,580
-2,682
| -7% | -$376K | 0.06% | 149 |
|
|
2025
Q4 | $4.7M | Buy |
38,262
+2,536
| +7% | +$308K | 0.06% | 160 |
|
|
2025
Q3 | $3.97M | Buy |
35,726
+8,807
| +33% | +$1M | 0.05% | 172 |
|
|
2025
Q2 | $2.98M | Buy |
26,919
+1,651
| +7% | +$176K | 0.05% | 198 |
|
|
2025
Q1 | $2.83M | Buy |
25,268
+890
| +4% | +$91.8K | 0.06% | 182 |
|
|
2024
Q4 | $2.25M | Buy |
24,378
+1,496
| +7% | +$135K | 0.05% | 222 |
|
|
2024
Q3 | $1.93M | Buy |
22,882
+2,043
| +10% | +$156K | 0.04% | 246 |
|
|
2024
Q2 | $1.43M | Sell |
20,839
-2,121
| -9% | -$142K | 0.03% | 262 |
|
|
2024
Q1 | $1.68M | Buy |
22,960
+1,816
| +9% | +$140K | 0.04% | 232 |
|
|
2023
Q4 | $1.71M | Buy |
21,144
+2,552
| +14% | +$199K | 0.05% | 204 |
|
|
2023
Q3 | $1.39M | Sell |
18,592
-475
| -2% | -$36.5K | 0.05% | 222 |
|
|
2023
Q2 | $1.47M | Sell |
19,067
-223
| -1% | -$17.8K | 0.05% | 217 |
|
|
2023
Q1 | $1.6M | Buy |
19,290
+50
| +0.3% | +$4.14K | 0.05% | 211 |
|
|
2022
Q4 | $1.65M | Buy |
+19,240
| New | +$1.52M | 0.06% | 200 |
|
|
2022
Q2 | $857K | Buy |
13,864
+5,710
| +70% | +$354K | 0.03% | 258 |
|
|
2022
Q1 | $485K | Sell |
8,154
-5,978
| -42% | -$382K | 0.02% | 397 |
|
|
2021
Q4 | $1.03M | Buy |
14,132
+7,040
| +99% | +$485K | 0.03% | 243 |
|
|
2021
Q3 | $448K | Sell |
7,092
-994
| -12% | -$69.8K | 0.02% | 260 |
|
|
2021
Q2 | $557K | Buy |
8,086
+1,645
| +26% | +$110K | 0.02% | 261 |
|
|
2021
Q1 | $416K | Sell |
6,441
-601
| -9% | -$38.8K | 0.02% | 247 |
|
|
2020
Q4 | $410K | Buy |
7,042
+507
| +8% | +$30.6K | 0.02% | 237 |
|
|
2020
Q3 | $413K | Sell |
6,535
-2,065
| -24% | -$143K | 0.03% | 207 |
|
|
2020
Q2 | $662K | Sell |
8,600
-940
| -10% | -$72K | 0.06% | 170 |
|
|
2020
Q1 | $713K | Buy |
9,540
+2,195
| +30% | +$152K | 0.08% | 136 |
|
|
2019
Q4 | $477K | Sell |
7,345
-344
| -4% | -$22.4K | 0.04% | 207 |
|
|
2019
Q3 | $487K | Buy |
7,689
+640
| +9% | +$41.8K | 0.04% | 198 |
|
|
2019
Q2 | $476K | Buy |
7,049
+285
| +4% | +$18.7K | 0.04% | 201 |
|
|
2019
Q1 | $440K | Buy |
6,764
+605
| +10% | +$40.2K | 0.04% | 201 |
|
|
2018
Q4 | $385K | Sell |
6,159
-1,375
| -18% | -$96.1K | 0.04% | 216 |
|
|
2018
Q3 | $582K | Buy |
7,534
+881
| +13% | +$66.5K | 0.05% | 194 |
|
|
2018
Q2 | $471K | Sell |
6,653
-887
| -12% | -$62.6K | 0.05% | 200 |
|
|
2018
Q1 | $568K | Buy |
7,540
+613
| +9% | +$48.7K | 0.06% | 176 |
|
|
2017
Q4 | $496K | Buy |
6,927
+569
| +9% | +$43.2K | 0.05% | 193 |
|
|
2017
Q3 | $515K | Sell |
6,358
-21
| -0.3% | -$1.61K | 0.06% | 190 |
|
|
2017
Q2 | $452K | Sell |
6,379
-35
| -0.5% | -$2.33K | 0.06% | 181 |
|
|
2017
Q1 | $436K | Buy |
6,414
+252
| +4% | +$17.7K | 0.06% | 180 |
|
|
2016
Q4 | $441K | Buy |
6,162
+3,488
| +130% | +$259K | 0.07% | 167 |
|
|
2016
Q3 | $212K | Sell |
2,674
-3,555
| -57% | -$289K | 0.04% | 216 |
|
|
2016
Q2 | $520K | Sell |
6,229
-285
| -4% | -$25.3K | 0.09% | 155 |
|
|
2016
Q1 | $598K | Sell |
6,514
-280
| -4% | -$25.3K | 0.11% | 109 |
|
|
2015
Q4 | $687K | Buy |
6,794
+99
| +1% | +$10.3K | 0.15% | 87 |
|
|
2015
Q3 | $657K | Buy |
6,695
+366
| +6% | +$40.6K | 0.18% | 92 |
|
|
2015
Q2 | $741K | Buy |
+6,329
| New | +$692K | 0.19% | 78 |
|
Other funds holding GILD
VCM
VPM
Coldstream Capital Management's GILD Position: Q1 2026 in Review
Coldstream Capital Management reduced its Gilead Sciences (GILD) stake by 7% in Q1 2026, selling an estimated $376K and leaving 35,580 shares worth $4.96M. The position accounts for 0.06% of the portfolio, ranked #149.
Coldstream Capital Management first reported a position in GILD in Q2 2015 and has held it in 43 quarters since. 2,316 funds tracked by Wall St. Rank hold GILD as of Q1 2026.
- Coldstream Capital Management held 35,580 shares of Gilead Sciences worth $4.96M as of Q1 2026.
- Coldstream Capital Management sold 2,682 Gilead Sciences shares in Q1 2026, an estimated $376K.
- Gilead Sciences made up 0.06% of Coldstream Capital Management's portfolio in Q1 2026, its #149 holding.
- Coldstream Capital Management first reported a position in Gilead Sciences in Q2 2015 and has held it in 43 quarters since.
- 2,316 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.
Based on Coldstream Capital Management's 13F filing for Q1 2026, filed 8 May 2026.